Determine the use of both corticosteroid and older steroid-sparing immunosuppressives in the treatment of myasthenia gravis
 

Evaluate the newer classes of medications approved for the treatment of myasthenia gravis and treatment considerations

Session date: 
03/04/2024 - 4:00pm to 5:00pm CST
Location: 
Virtually
United States
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
John Sturgis, MD, Resident